SereNeuro Therapeutics, a preclinical biotechnology company developing non-opioid pain therapies, unveiled new data today on a novel approach to chronic pain management and joint tissue preservation. The data highlights SN101, a first-in-class induced pluripotent stem cell (iPSC)-derived therapy.<\/p>\n
SN101 utilizes mature iPSC-derived peripheral pain-sensing neurons (nociceptors) to treat chronic osteoarthritis joint pain. The data highlights a scientific approach that challenges traditional pain management logic.<\/p>\n
“Our approach utilizes high-purity, iPSC-derived nociceptors (SN101) that effectively function as a sponge for pain factors. By injecting SN101 cells, we counterintuitively relieve pain and halt cartilage degradation,” said Gabsang Lee, scientific co-founder of SereNeuro and a professor of neurology and neuroscience at Johns Hopkins University.<\/p>\n
SN101 neurons function as a therapeutic sponge by sequestering inflammatory pain factors without transmitting pain signals to the brain. Additionally, the cells secrete mechanistically-confirmed regenerative factors, positioning SN101 as a disease-modifying osteoarthritis drug (DMOAD).<\/p>\n
The presentation distinguishes SN101 from emerging single-target therapies, such as Nav 1.8 inhibitors. While ion channel inhibitors are designed to block a solitary pathway, SN101 cells express all canonical pain receptors and ion channels. This biological complexity allows SN101 therapy to inherently operate on all channels simultaneously to downregulate pain and inflammation<\/a>.<\/p>\n Furthermore, the data contrasts SN101 with current standards, such as corticosteroids.<\/p>\n “Current standard-of-care treatments, particularly corticosteroids, provide temporary relief but are known to accelerate cartilage degradation over time, ultimately worsening the disease,” said Dr. Dani\u00ebl Saris, a member of SereNeuro’s Clinical Advisory Board and a professor of orthopedics and regenerative medicine at Mayo Clinic.<\/p>\n In contrast to those degenerative effects, SN101 creates an environment that preserves joint tissues and relieves chronic pain<\/a>, without the risk of addiction.<\/p>\n Source:<\/p>\n